Using synthetic peptide or recombinant protein as immunising antigens we have produced monoclonal antibodies and polyclonal antisera directed against targets of particular interest in leukaemia diagnosis. In this way we have prepared reagents which recognise all T or all B lymphocytes in routinely fixed paraffin sections which are unique in this respect. We have also produced monoclonal antibodies to molecules potentially involved in specific neoplastic transformations, implicated by virtue of the involvement of their genes in chromosomal defects in these neoplasms. In particular, we have produced antibodies recognising bcl-2, involved in follicular lymphoma, tal-1, involved in T-cell acute leukaemias and HRX involved in a variety of hematologic disorders. The application of these reagents to diagnosis has so far proved useful. In addition their use outside the field of leukaemia diagnosis has proved to be even more important in some cases.
Skip Nav Destination
Article navigation
Research Article|
December 01 1995
Novel leukaemia markers
Kingsley J. Micklem
Kingsley J. Micklem
1Department of Cellular Science, Room 5501, John Radcliffe Hospital, Oxford, OX3 9DU, U.K.
Search for other works by this author on:
Publisher: Portland Press Ltd
Received:
September 08 1995
Online ISSN: 1573-4935
Print ISSN: 0144-8463
© 1995 Plenum Publishing Corporation
1995
Biosci Rep (1995) 15 (6): 463–468.
Article history
Received:
September 08 1995
Citation
Kingsley J. Micklem; Novel leukaemia markers. Biosci Rep 1 December 1995; 15 (6): 463–468. doi: https://doi.org/10.1007/BF01204349
Download citation file:
Sign in
Don't already have an account? Register
Sign in to your personal account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Biochemical Society Member Sign in
Sign InSign in via your Institution
Sign in via your InstitutionGet Access To This Article
5
Views
Cited By
Open Access for all
We offer compliant routes for all authors from 2025. With library support, there will be no author nor reader charges in 5 journals. Check here |
![]() |